

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE: CARTON 20 ML AND  
50 ML**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for dogs and cats

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. PACKAGE SIZE**

20 ml

50 ml

**4. TARGET SPECIES**

Dogs, cats

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Dogs: single intravenous or subcutaneous injection.

Cats: single subcutaneous injection.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once broached use by....

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Emdoka

**14. MARKETING AUTHORISATION NUMBERS**

Vm 34534/5004

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING**  
**UNITS: LABEL 20 ML AND 50 ML**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for dogs and cats

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use by....

Once broached, use within 28 days.

**PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

**PACKAGE LEAFLET**

**1. Name of the veterinary medicinal product**

Emdocam 5 mg/ml solution for injection for dogs and cats

**2. Composition**

Each ml contains:

**Active substance:**

Meloxicam 5 mg

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Ethanol	150 mg

Clear yellow solution.

**3. Target species**

Dogs and cats

**4. Indications for use**

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

**5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in pregnant or lactating dogs and cats.

Do not use in dogs and cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in dogs and cats less than 6 weeks of age nor in cats of less than 2 kg.

## **6. Special warnings**

### Special warnings:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice. Any oral follow-up therapy using meloxicam or other NSAIDs should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Meloxicam may cause allergic reactions. People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Accidental self-injection may give rise to pain. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

### Pregnancy and lactation:

Do not use in pregnant or lactating dogs or cats.

### Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

### Overdose:

In case of overdose symptomatic treatment should be initiated.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**7. Adverse events**

Dogs, cats:

Rare (1 to 10 animals / 10 000 animals treated):	Appetite loss <sup>1</sup> , lethargy <sup>1</sup> Vomiting <sup>1</sup> , diarrhoea <sup>1</sup> , blood in faeces <sup>1,2</sup> Renal failure <sup>1</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Haemorrhagic diarrhoea <sup>1</sup> , haematemesis (vomiting blood) <sup>1</sup> , gastric ulcer <sup>1</sup> , small intestine ulcer <sup>1</sup> Elevated liver enzymes <sup>1</sup> Anaphylactoid reaction <sup>3</sup>

<sup>1</sup>These adverse events occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

<sup>2</sup>Occult.

<sup>3</sup>Should be treated symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

**8. Dosage for each species, routes and method of administration**

For subcutaneous or intravenous use.

**Dogs:**

Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

**Cats:**

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

As the vial should not be broached more than 50 times the user should select the most appropriate vial size according to the target species to be treated.

**9. Advice on correct administration**

Avoid introduction of contamination during use.

**10. Withdrawal periods**

Not applicable.

**11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month. Shelf life after first opening the immediate packaging: 28 days

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 34534/5004

Pack sizes:

Cardboard box containing 1 vial of 20 ml

Cardboard box containing 1 vial of 50 ml

Not all pack sizes may be marketed.

**15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

**16. Contact details**

Marketing authorisation holder:

Emdoka bvba

John Lijzenstraat 16

B-2321 Hoogstraten

Belgium

Tel: +32 (0)3 315 04 26, [info@emdoka.be](mailto:info@emdoka.be)

Manufacturer responsible for batch release:

Produlab Pharma B.V.

Forellenweg 16

4941 SJ Raamsdonksveer

The Netherlands

Local representatives and contact details to report suspected adverse events:

DUGV (UK) Ltd.

Union House, 111 New Union Street

Coventry, CV1 2NT

United Kingdom

Tel: +353 (0) 504 43169

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**17. Other information**

POM-V

*Gavin Hall*  
Approved: 26 March 2026